Global Psychiatrists

08/11/2025

Germany's quantum computer designed new antibiotics — ending resistance in days

Researchers at the Max Planck Institute used quantum algorithms to model 500 million molecular combinations simultaneously, identifying antibiotics that bacteria physically cannot develop resistance against. Traditional computers would take centuries; the quantum system did it in 72 hours.

The breakthrough targets a different mechanism: instead of attacking bacterial cell walls (which they evolve to strengthen), these antibiotics disrupt quantum electron tunneling in bacterial energy production. Since this is a fundamental physics process, bacteria can't mutate around it — it would be like evolving to ignore gravity.

This addresses one of humanity's scariest threats: antibiotic-resistant superbugs kill 1.3 million people annually, projected to reach 10 million by 2050. Current antibiotics are failing. These quantum-designed drugs tested successfully against MRSA, E. coli, and drug-resistant tuberculosis, with zero resistance development after 1,000 generations.

First human trials start 2025. Quantum computing might have just saved modern medicine from collapse. ⚛️

Source: Max Planck Institute for Quantum Optics, 2024

01/11/2025

24/10/2025

23/10/2025

🛡️ Standing Up Against Retaliation: Help Fund My Legal Defense

I spoke up when it mattered most—making a protected disclosure in good faith to safeguard patients’ health, safety, and dignity. In response, I’m now facing intense legal retaliation.

This isn’t just about me. It’s about defending the right to speak truth to power, protecting whistleblowers, and upholding transparency in healthcare.

Legal costs are mounting, and I need your support to fight back. Every contribution helps me stand firm in the face of injustice.

Dr. Jain has dedicated over 20 years to improving NHS patient safety but faced severe retaliation for raising concerns about unsafe practices. Your support can help fund legal action to protect whistleblowers and ensure a safer healthcare system for everyone. Please consider donating or sharing this message to help stop gagging those doctors for whom patient safety comes first. Thank you!

https://gofund.me/dc8aca35a - - - Donate here

Thank you for standing with me.

WhistleblowerProtection

23/10/2025

Seeking your kind Help to fight the legal battle against those who have subjected me to various detrimental serious consequences due to whistleblowing

Hello, I am Dr. Jain, a dedicated NHS Locum consultant Psychiatr… Rajesh JAIN needs your support for £10000 Please help those so that they can help others

17/10/2025

Please help to those who help others. Your kind donation will help in restoring the justice through appeal process.

Vijay kindly supported me during my time of need and I am simply paying that kindness back.

16/10/2025

Several promising gene therapies are currently in the pipeline, advancing through clinical trials and expected to seek regulatory approval in the coming years, primarily targeting rare diseases, oncology, and neurological disorders.

These therapies leverage viral vectors, CRISPR editing, or other delivery methods to address genetic defects.

Below is a list of notable pipeline gene therapies and their target diseases, based on recent industry reports as of 2025.

- AMT-130: Huntington's disease

- AMT-191: Fabry disease

- ST-920: Fabry disease
- RP-A501: Danon disease

- PRGN-2012 (zopapogene imadenovec-drba): Recurrent respiratory papillomatosis

- RGX-121: Hunter syndrome (MPS II)

- RGX-111: Mucopolysaccharidosis type IIIA (Sanfilippo syndrome)

- TSHA-102: Rett syndrome

- TSHA-105: SLC13A5 deficiency

- TSHA-118: CLN1 disease

- Etuvetidigene autotemcel: Wiskott-Aldrich syndrome

- UX111: Mucopolysaccharidosis type IIIA (Sanfilippo syndrome)

- Deramiocel: Duchenne muscular dystrophy cardiomyopathy

- NRTX-1001: Epilepsy (focal cortical dysplasia)

- Kresladi (marnetegragene autotemcel): Leukocyte adhesion deficiency

- Pariglasgene brecaparvovec (DTX401): Glycogen storage disease Ia (miscellaneous metabolic diseases)

- Revascor (rexlemestrocel-L): Heart failure/high blood pressure

- Sonpiretigene isteparvovec (MCO-010): Heart failure/high blood pressure

- Zevorcabtagene autoleucel: Multiple myeloma

This pipeline is robust, with over 1,000 gene therapy programs in development globally, heavily focused on oncology (e.g., myeloma, leukemia, lymphoma) and rare genetic disorders like cystic fibrosis, hemophilia A, and thalassemia, where more than 30 therapies are active in late stages. Many are pursuing accelerated FDA approval pathways, potentially leading to new treatments by 2026

16/10/2025

In last few years only FDA has approved gene therapies for----

Name of treatment: Name of disease

- Hemgenix: Hemophilia B
- Roctavian: Hemophilia A
- Elevidys: Duchenne muscular dystrophy
- Casgevy: Sickle cell disease
- Lyfgenia: Sickle cell disease
- Zynteglo: Beta-thalassemia
- Vyjuvek: Dystrophic epidermolysis bullosa
- Skysona: Cerebral adrenoleukodystrophy
- Lenmeldy: Metachromatic leukodystrophy

16/10/2025

Organoid AI and Quantum AI have great potential to advance precision psychiatry significantly.

Organoid AI involves using brain organoids—miniature, lab-grown models of human brain tissue—combined with artificial intelligence to better understand the complex biological and genetic factors behind psychiatric disorders. This approach allows for personalized insights into how different brains function and respond to treatments, enabling more targeted and effective therapies.

Quantum AI leverages the principles of quantum computing and AI to process vast amounts of complex data much faster than traditional computers. It can help identify patterns and relationships within genetic, biochemical, and clinical data that are otherwise too intricate to analyze. Together, these technologies can provide deep, personalized understanding of mental illnesses at a molecular and systems level, advancing precision psychiatry by tailoring treatments to individual patients’ unique biological and psychological profiles.

By integrating these advanced AI technologies, clinicians and researchers can develop better diagnostic tools, predict treatment responses, and design customized interventions, ultimately improving outcomes for patients with psychiatric conditions.

This represents a promising future direction for psychiatry and mental health care.

16/10/2025

suramin has been approved for use in humans, specifically for treating certain parasitic infections. It is an established treatment for the early stages of African sleeping sickness caused by Trypanosoma brucei rhodesiense and has also been used for river blindness (onchocerciasis). Its approval is limited to these infectious diseases, and it is administered by injection under medical supervision due to potential side effects.

Suramin has not been broadly approved for other uses such as autism or cancer; in these areas, it remains experimental and is available only in research settings or clinical trials. Its use outside approved indications requires careful medical oversight and is not standard practice. So, while suramin is approved for specific human diseases, its use beyond those is still under study

16/10/2025

So basically Leucovorin is prescribed/effective in Cerebral Folate Deficiency (CFD) in which some of the symptoms are also there beside other symptoms

Yes, that is correct. Leucovorin (folinic acid) is primarily prescribed and effective in treating Cerebral Folate Deficiency (CFD), a condition caused by folate receptor autoantibodies that block folate transport into the brain. Many children with CFD show symptoms that overlap with autism spectrum disorder (ASD), such as developmental delays, speech and language difficulties, behavioral issues, and other neurological symptoms. Because leucovorin can bypass the blocked receptors and deliver folate directly to the brain, it helps improve those symptoms associated with CFD, including some that resemble or occur alongside autism symptoms.

In summary, leucovorin is especially useful for children diagnosed with CFD, which often includes symptoms seen in autism, making it a targeted therapy that can improve brain function and developmental outcomes when the folate